FibroGen Inc

FGEN:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:24 PM EST
48.32quote price arrow up+0.76 (+1.60%)
Volume
342,049
52 week range
22.65 - 51.56

...

Loading . . .

KEY STATS

  • Open47.44
  • Day High48.94
  • Day Low46.87
  • Prev Close47.56
  • 52 Week High51.56
  • 52 Week High Date09/03/20
  • 52 Week Low22.65
  • 52 Week Low Date03/19/20
  • Market Cap4,397.60M
  • Shares Out91.01M
  • 10 Day Average Volume0.73M
  • Dividend-
  • Dividend Yield-
  • Beta1.47
  • 1 Year % Change16.89

RATIOS/PROFITABILITY

  • EPS (TTM)-2.62
  • P/E (TTM)-18.43
  • Fwd P/E (NTM)-57.18
  • EBITDA (MRQ)-212.74M
  • ROE (MRQ)-43.74%
  • Revenue (MRQ)119.30M
  • Gross Margin (MRQ)94.00%
  • Net Margin (MRQ)-191.78%
  • Debt To Equity (MRQ)13.16%

EVENTS

  • Earnings Date03/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest FibroGen Inc News

There is no recent news for this security.

Latest FGEN News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for...
James Schoeneck
Chairman
Enrique Conterno
Chief Executive Officer
Pat Cotroneo
Chief Financial Officer
Address
409 Illinois St
San Francisco, CA
94158-2509
United States